Quick Answer
XTL BIOPHARMACEUTICALS LTD reported R&D Expense of $98.0 thousand for fiscal year 2024.
XTL BIOPHARMACEUTICALS LTD R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $98.0K | +216.1% |
| 2023 | $31.0K | +3.3% |
| 2022 | $30.0K | +0.0% |
| 2021 | $30.0K | -21.1% |
| 2020 | $38.0K | +8.6% |
| 2019 | $35.0K | -7.9% |
| 2018 | $38.0K | -11.6% |
| 2017 | $43.0K | -90.3% |
| 2016 | $443.0K | -23.4% |
| 2015 | $578.0K | — |
- XTL BIOPHARMACEUTICALS LTD showed an increase of +216.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2024 period, XTL BIOPHARMACEUTICALS LTD’s r&d expense has declined by 83.0% (from $578.0 thousand to $98.0 thousand).
- The most recent figure is from XTL BIOPHARMACEUTICALS LTD’s fiscal year 2024 report (Form 20-F), filed with the SEC on April 30, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: